11/10/2026
What happens when 15 of Israel’s leading academic and medical institutions decide to collaborate instead of compete?
INBI, the Israel National Biotech Innovation Centre is born: a new national initiative designed to turn groundbreaking biomedical research into medicines and treatments that can ultimately reach patients.
Bar-Ilan University is proud to be one of the partners in this initiative, alongside Israel’s leading universities, hospitals, and healthcare organizations.
INBI was established to address one of the major challenges facing Israel’s life sciences sector: the gap between a promising discovery in the lab and a development mature enough to become an investment opportunity, a partnership with a pharmaceutical company, or a startup.
To bridge that gap, the initiative plans to raise $500 million in philanthropic money and provide Israel’s most promising research projects with the expertise, infrastructure, capital, connections, and capabilities needed to advance them from academia to industry.
The initiative is led by Samuel Moed, formerly a senior executive at Bristol Myers Squibb, as Chair of INBI, and Dr. Anat Cohen-Dayag, Executive Chairperson of Compugen, as CEO of INBI Core.
This is an extraordinary collaboration on an Israeli scale and, more importantly, an opportunity to significantly increase our ability to turn the outstanding science being conducted here into real impact on human health in Israel and around the world.
We are proud to be part 👏